Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist

BACKGROUND: Experimental cancer vaccines are traditionally administered by injection in subcutaneous tissue or muscle, commonly with adjuvants that create chronic inflammatory depots. Injection of melanoma-derived peptides induces T cell responses; however, the depots that form following injection m...

Descripción completa

Detalles Bibliográficos
Autores principales: Meneveau, Max O, Petroni, Gina R, Salerno, Elise P, Lynch, Kevin T, Smolkin, Mark, Woodson, Elizabeth, Chianese-Bullock, Kimberly A, Olson, Walter C, Deacon, Donna, Patterson, James W, Grosh, William W, Slingluff, Craig L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154977/
https://www.ncbi.nlm.nih.gov/pubmed/34035112
http://dx.doi.org/10.1136/jitc-2020-002214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154977/
https://www.ncbi.nlm.nih.gov/pubmed/34035112
http://dx.doi.org/10.1136/jitc-2020-002214

Ejemplares similares